- Wave of Debt Payments Facing US Government
- US Job Losses to Bottom out Next Quarter: NABE
- Little Sign of Inflation on the Horizon: IMF
- Kraft Weighs Higher Cadbury Bid as Rivals Circle
- MBS Program Should be Extended: Fed's Bullard
- JPMorgan's Dimon Could Succeed Geithner: Report
- Wall Street Finds Profits by Reducing Mortgages
- Microsoft, News Corp Weigh Online News Pact
- Senate Democrats at Odds Over Health Care Bill
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- U.S. Stocks Slip, Dollar Rises
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
Text Size 
Did Martha Stewart miss out on a big payday on ImClone stock?
 |
Frank Franklin Ii / AP |
Bristol-Myers Squibb's [BMY
Loading...
()
] proposal to buy ImClone Systems [IMCL
Loading...
()
] for $4.5 billion brings back memories of the 2002 insider trading scandal that landed the domestic diva in jail and made ImClone a household word.
Stewart, who sold her ImClone stock in 2001—allegedly on a tip from ImClone founder Sam Waksal—got $58.43 a share, or a total of $229,513. She ended up being convicted in 2004 of lying to federal prosecutors about the circumstances surrounding the sale and spent five months in prison.
Now, Bristol-Myers Squibb is offering $60 for ImClone, so if Stewart had held onto her stock, she would've made a paltry $6,000 more seven years later.
But if she had waited until June 2004, when ImClone shares rose as high as $87, the payout would have been $112,223 more.
Stewart sold her stock allegedly on worries that the Food and Drug Administration was going to reject Erbitux, ImClone's colon cancer drug. Ironically, ImClone recently received positive reviews for the drug's efficacy on colon cancer and head and neck cancer. It is in the late stage of testing its effects on pancreatic cancer and may soon file with the FDA to investigate its effects on lung cancer.
What's more, former CEO Sam Waksal, who pleaded guilty to six criminal charges of perjury, securities fraud, bank fraud and obstruction of justice in August 2002, finishes his seven years and three months in prison next week.
Print
Email
- Technology can make or break a fortune in the world of alternative energy.
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- Many people are facing the holidays with substantially smaller incomes. Here’s how some are adapting.
- The Victoria's Secret Fashion Show attracts a big TV audience every year, but this year it may take on even more importance.
- Jim Cramer is a proponent of stocks that pay healthy dividends, and here are his top five dividend plays.
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes